Colgate India: Brokerages set ₹2,700 target in FY26

Why Colgate-Palmolive (India) is back on analysts’ radar

Colgate-Palmolive (India) has drawn fresh brokerage attention after multiple quarterly updates and management commentary highlighted a mix of steady margins, uneven volumes, and portfolio premiumisation. Research houses have issued ratings ranging from Buy to Sell, and price targets that span a wide band. The divergence is visible both after the company’s January-March 2026 quarter and again after its September quarter (Q2 FY26) performance.

Two themes show up repeatedly in broker notes: whether volume growth can stabilise without heavy discounting, and how quickly the business normalises after GST-related disruption that triggered temporary destocking across channels.

Nomura turns positive, raises target to ₹2,500

Nomura upgraded the stock from ‘Reduce’ to ‘Buy’ and raised its target price to ₹2,500 per share from ₹2,050. The revised target was stated to be around 16% above the previous closing price cited in the report.

Nomura said Colgate’s core business appears to be returning to a more normal trajectory, with the company pushing premium products to support growth and margins. It also flagged that earnings growth in FY26 remained stable but expected an improvement in FY27 with double-digit growth. A key driver in Nomura’s view is better volume performance. The brokerage highlighted a 4.5% jump in volume growth in the January-March 2026 quarter and said it does not expect a volume decline.

Jefferies stays constructive with targets up to ₹2,700

Jefferies maintained a ‘Buy’ view in multiple notes referenced, with target prices cited at ₹2,600 per share in one instance and ₹2,700 per share in another. The ₹2,600 target was described as around 20% above the previous closing price cited in that note. In the September quarter coverage, Jefferies pegged the target at ₹2,700 per share.

Jefferies attributed the weak September quarter trend largely to temporary GST-related destocking and a high base. It also said Colgate’s premium segment remained resilient. At the same time, the brokerage cut its EPS estimates by 4-5% and noted the stock may remain rangebound until growth improves.

How the street is split: analyst rating mix

After the company’s quarterly results, one snapshot cited that among 31 analysts tracking the stock, 8 rated it ‘Buy’, 12 ‘Hold’, and 11 ‘Sell’. A later snapshot cited that among 33 analysts, 10 rated it ‘Buy’, 11 ‘Hold’, and 12 ‘Sell’.

The change reflects how coverage can shift over time, but the broader takeaway remains that consensus is not one-sided. A meaningful portion of the street is waiting for stronger evidence on volume recovery and competitive positioning.

January-March 2026 results: profit flat, sales up 9%

For the January-March 2026 quarter, Colgate reported net profit of ₹353.32 crore, marginally lower than ₹355.00 crore a year earlier. Sales rose 9% year-on-year to ₹1,582.77 crore compared with ₹1,452.02 crore in the March 2025 quarter.

For the full FY2025-26 year, net profit fell 7.7% to ₹1,325.31 crore, while total consolidated income slipped marginally to ₹6,124.16 crore. Brokerages discussing the quarter linked the growth effort to premium products and improving operating momentum in the core franchise.

September quarter (Q2 FY26): profit down 17%, GST cuts hit volumes

In the September quarter (Q2 FY26), the company reported a 17% year-on-year decline in net profit to about ₹327.5 crore to ₹328 crore, described as in line with expectations. Revenue fell 6.2% year-on-year to ₹1,519.5 crore. EBITDA declined 6.6% to ₹464.5 crore, while operating margin stayed stable at 30.6%.

Sequentially, sales were reported to have risen about 6% from the previous quarter, signalling early signs of normalisation. Colgate said a GST rate cut on oral care products led to temporary destocking at distributors and retailers, which affected the quarter’s performance. CEO Prabha Narasimhan said the company expects a gradual recovery in the second half of the year.

Where key brokerages stand: ratings and targets

The brokerage range remains wide, with Buy calls based on recovery and premium resilience, and Sell calls anchored in valuation concerns and weak volume trends.

Stock move and immediate market reaction

Colgate-Palmolive (India) shares were reported at ₹2,213.90 on the BSE, down 3.27% on the day, after falling as much as 3.85% intraday to ₹2,200.60 amid the mixed brokerage commentary.

In another reference point, the stock was said to have closed 1.74% higher at ₹2,300 ahead of the September quarter-related brokerage notes. The price action underscores how quickly sentiment can swing as investors weigh near-term disruption against the pace of recovery.

Dividend: ₹24 per share and where yield stacks up

The board declared an interim dividend of ₹24 per share for FY2025-26, with different notes citing different timelines. One update stated a second interim dividend of ₹24 per share with a record date of 1 June 2026 and payment on or after 17 June. Another note on the September quarter said the interim dividend would be payable from November 19.

The article also included a dividend yield comparison that places Colgate among higher-yielding payers within the Indian market.

Market impact: what investors are watching next

Brokerages that are cautious have repeatedly pointed to three risks: weak volumes, higher competitive intensity, and margin pressure from rising advertising spend. Some notes also flagged GST-related challenges and the possibility that elevated competition keeps growth volatile.

On the other side, more constructive views argue that core oral care customers remain sticky, premium products are holding up, and sequential sales improvement could signal that disruption is fading. Several broker notes explicitly framed the GST rate cut impact as temporary destocking rather than permanent demand loss.

Analysis: why the divergence in targets is so wide

The spread in target prices from ₹1,800 to ₹2,870 reflects different assumptions about the durability of margins and the speed of volume recovery. Bears highlight valuation and limited near-term triggers, including one note that described the stock trading at around 40 times FY27 estimated earnings, leaving “very little” upside. Bulls are leaning on premiumisation, stable operating margin near 30%, and the expectation that normalisation in distribution will lift growth in the second half.

The next key variable is execution. If volume trends stabilise alongside premium-led mix gains, the optimistic FY27 double-digit EPS expectations cited by some brokerages become easier to underwrite. If volumes remain soft amid competition, cautious ratings are likely to persist.

Conclusion

Colgate-Palmolive (India) remains a stock where the near-term narrative is driven by volumes, channel inventory behaviour after GST changes, and the company’s ability to defend share through premiumisation. Brokerages are split, with targets clustered in a broad ₹1,800 to ₹2,700-plus band and ratings spread across Buy, Hold, and Sell. Investors will watch upcoming quarters for clearer evidence of sustained volume recovery and how advertising and competitive intensity shape margins.